Reauthorizes and revises the user fee program that the FDA uses to fund oversight of over-the-counter monograph drugs through fiscal year 2030, setting new fee amounts and collection schedules, and adds requirements on sunscreen rules, Rx-to-nonprescription switch guidance, and supply chain reporting.

• Sets facility and order request fee revenue for fiscal years 2026 through 2030, with fee amounts and due dates changed from prior years
• Allows a one-time fee increase in fiscal years 2028, 2029, or 2030 if facility counts exceed a set threshold
• Requires FDA to report on order request timelines, safety activities, and sunscreen active ingredient review, and to publish negotiation meeting minutes
• Directs the Comptroller General to report on the over-the-counter drug supply chain by September 30, 2027, and sets guidance deadlines for switching prescription drugs to nonprescription use

• Health, Education, Labor, and Pensions Committee (Senate)

Health